Fulcrum's Losmapimod Improves Multiple Measures, But Not Primary Endpoint :: Scrip
Local administration of ACE-083 in wild-type mice causes dose-dependent... | Download Scientific Diagram
ACE-083 to Treat FSHD Earns FDA 's Fast Track Designation
Cells | Free Full-Text | Outcome Measures in Facioscapulohumeral Muscular Dystrophy Clinical Trials
Rare Disease Report on X: "Facioscapulohumeral #MuscularDystrophy treatment, ACE-083, increases muscle volume in patients with #FSHD in part 1 of a 2-part phase 2 study, helping it land an orphan drug designation
Form 8-K ACCELERON PHARMA INC For: Oct 23
Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy: Trends in Molecular Medicine
Q&A on A083-02: the Phase 2 ACE-083 Clinical Study in FSHD
Acceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle Society
Acceleron to Discontinue its P-II Study of ACE-083 for Facioscapulohumeral Muscular Dystrophy
Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease | Neurology
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy - Statland - 2022 - Muscle & Nerve - Wiley Online Library
ACE-083 is designed to improve FSHD patients' strength and muscular growth | FindATopDoc
Acceleron's ACE-083 could succeed in muscle growth but long-term functional benefit may be limited | by Richardwilliam | Medium
PDF) Locally Acting ACE-083 Increases Muscle Volume in Healthy Volunteers
2018 FSHD Connect presentation by Acceleron - YouTube
Document
Acceleron Ends ACE-083 FSHD Testing After Phase II Failure :: Scrip
Randomized phase 2 study of ACE‐083, a muscle‐promoting agent, in facioscapulohumeral muscular dystrophy - Statland - 2022 - Muscle & Nerve - Wiley Online Library
Local administration of ACE-083 in wild-type mice causes dose-dependent... | Download Scientific Diagram
Statland_Results from a Phase 2 Study of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy (FSHD) – Implications for Future Clinical Trials
Statland et al MDA 2019 FSHD presentation DRAFT
Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy
Encouraging Results for ACE-083 in FSHD - Muscular Dystrophy Association
Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease | Scientific Reports
xlrn201719ex992
